Brief: SK Bioscience Applies For Conditional Approval For Its COVID-19 Vaccine Skycovione To EMA
01/08/2022 24:36
Aug 1 (Reuters) - SK Bioscience Co Ltd 302440.KS :
* APPLIES FOR CONDITIONAL APPROVAL FOR ITS COVID-19 VACCINE
SKYCOVIONE TO EUROPEAN MEDICINES AGENCY
Further company coverage: 302440.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine